Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 163

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2012', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Chronic Kidney Disease (Chronic Renal Failure) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Products under Development, Key Players in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics, Chronic Kidney Disease (Chronic Renal Failure) Pipeline Overview, Chronic Kidney Disease (Chronic Renal Failure) Pipeline, Chronic Kidney Disease (Chronic Renal Failure) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Products under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Hospira, Inc.
Abbott Laboratories
Amgen Inc.
Eli Lilly and Company
Rockwell Medical Technologies, Inc.
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
MD Scientific, LLC
Astellas Pharma Inc.
LEO Pharma A/S
Pfizer Inc.
Nile Therapeutics, Inc.
Ocera Therapeutics, Inc.
Proteon Therapeutics, Inc.
Hawthorn Pharmaceuticals, Inc.
Promedior, Inc.
Cytochroma Inc.
Reata Pharmaceuticals, Inc.
Angion Biomedica Corp.
Thrasos, Inc.
Concert Pharmaceuticals, Inc.
CorMedix, Inc.
Vitae Pharmaceuticals, Inc.
KAI Pharmaceuticals Inc.
Stelic Institute & Co.
Zenyaku Kogyo Co., Ltd.
Sorbent Therapeutics, Inc.
InVasc Therapeutics, Inc.
Varinel, Inc.
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aranesp - Drug Profile
YM533 - Drug Profile
Bardoxolone Methyl - Drug Profile
PRT-201 - Drug Profile
CU-NP - Drug Profile
AST-120 - Drug Profile
LEO 27847 - Drug Profile
THR-123 - Drug Profile
siRNA For Chronic Diseases - Drug Profile
G Family Inhibitor For CKD - Drug Profile
CTA018 - Drug Profile
VTP-27999 - Drug Profile
KAI-4169 - Drug Profile
KAI-4169 - Drug Profile
Sodium Bicarbonate - Drug Profile
CLP 1001 - Drug Profile
CLP 1004 - Drug Profile
SFP-Hemodialysis - Drug Profile
Lipitor - Drug Profile
18B Glycyrrhetinic Acid - Drug Profile
PF-00489791 - Drug Profile
Everolimus - Drug Profile
VAR-10100 - Drug Profile
Benazepril - Drug Profile
Valsartan - Drug Profile
Benazepril + Valsartan - Drug Profile
Nesiritide - Drug Profile
Floxapen - Drug Profile
Folate + Pyridoxine + Cyanocobalamin - Drug Profile
Renagel + Cinacalcet - Drug Profile
Irbesartan - Drug Profile
LY2382770 - Drug Profile
Neo-Kidney Augment - Drug Profile
MK3102 - Drug Profile
CRMD-001 - Drug Profile
Simulect + Myfortic + Certican + Prednisolone - Drug Profile
IDEC-C2B8 - Drug Profile
Siran - Drug Profile
Ramipril + Telmisartan - Drug Profile
Silymarin - Drug Profile
haw Nuv15 - Drug Profile
haw Nuv16 - Drug Profile
INV-144 - Drug Profile
Nautiol - Drug Profile
ABT-614 - Drug Profile
N-Acetylcysteine - Drug Profile
LY2623091 - Drug Profile
Renvela - Drug Profile
Zemplar - Drug Profile
Biosimilar Erythropoietin - Drug Profile
Paricalcitol - Drug Profile
CTP-499 - Drug Profile
Subcutaneous rhPTX-2 - Drug Profile
Hypertonic Saline Solution - Drug Profile
Drug For CRD - Drug Profile
ANG-3070 - Drug Profile
ANG-4011 - Drug Profile
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Drug Profile Updates
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Dormant Products
Chronic Kidney Disease (Chronic Renal Failure) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2012
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Hospira, Inc., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Eli Lilly and Company, H1 2012
Rockwell Medical Technologies, Inc., H1 2012
Quark Pharmaceuticals, Inc., H1 2012
Merck & Co., Inc., H1 2012
MD Scientific, LLC, H1 2012
Astellas Pharma Inc., H1 2012
LEO Pharma A/S, H1 2012
Pfizer Inc., H1 2012
Nile Therapeutics, Inc., H1 2012
Ocera Therapeutics, Inc., H1 2012
Proteon Therapeutics, Inc., H1 2012
Hawthorn Pharmaceuticals, Inc., H1 2012
Promedior, Inc., H1 2012
Cytochroma Inc., H1 2012
Reata Pharmaceuticals, Inc., H1 2012
Angion Biomedica Corp., H1 2012
Thrasos, Inc., H1 2012
Concert Pharmaceuticals, Inc., H1 2012
CorMedix, Inc., H1 2012
Vitae Pharmaceuticals, Inc., H1 2012
KAI Pharmaceuticals Inc., H1 2012
Stelic Institute & Co., H1 2012
Zenyaku Kogyo Co., Ltd., H1 2012
Sorbent Therapeutics, Inc., H1 2012
InVasc Therapeutics, Inc., H1 2012
Varinel, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Drug Profile Updates
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2012
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013